244 related articles for article (PubMed ID: 27748182)
1. Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.
Macedonio G; Stefanucci A; Maccallini C; Mirzaie S; Novellino E; Mollica A
Protein Pept Lett; 2016; 23(12):1045-1051. PubMed ID: 27748182
[TBL] [Abstract][Full Text] [Related]
2. Characterization of pepcan-23 as pro-peptide of RVD-hemopressin (pepcan-12) and stability of hemopressins in mice.
Glasmacher S; Gertsch J
Adv Biol Regul; 2021 May; 80():100808. PubMed ID: 33799079
[TBL] [Abstract][Full Text] [Related]
3. Effects of the cannabinoid 1 receptor peptide ligands hemopressin, (m)RVD-hemopressin(α) and (m)VD-hemopressin(α) on memory in novel object and object location recognition tasks in normal young and Aβ1-42-treated mice.
Zhang RS; He Z; Jin WD; Wang R
Neurobiol Learn Mem; 2016 Oct; 134 Pt B():264-74. PubMed ID: 27481221
[TBL] [Abstract][Full Text] [Related]
4. Further Characterization of Hemopressin Peptide Fragments in the Opioid and Cannabinoid Systems.
Szlavicz E; Perera PS; Tomboly C; Helyes Z; Zador F; Benyhe S; Borsodi A; Bojnik E
Anesth Analg; 2015 Dec; 121(6):1488-94. PubMed ID: 26465932
[TBL] [Abstract][Full Text] [Related]
5. Signaling molecules targeting cannabinoid receptors: Hemopressin and related peptides.
Wei F; Zhao L; Jing Y
Neuropeptides; 2020 Feb; 79():101998. PubMed ID: 31831183
[TBL] [Abstract][Full Text] [Related]
6. Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice.
Li XH; Lin ML; Wang ZL; Wang P; Tang HH; Lin YY; Li N; Fang Q; Wang R
Neurogastroenterol Motil; 2016 Jun; 28(6):891-9. PubMed ID: 26991932
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
8. Anorexigenic effects induced by RVD-hemopressin(α) administration.
Ferrante C; Recinella L; Leone S; Chiavaroli A; Di Nisio C; Martinotti S; Mollica A; Macedonio G; Stefanucci A; Dvorácskó S; Tömböly C; De Petrocellis L; Vacca M; Brunetti L; Orlando G
Pharmacol Rep; 2017 Dec; 69(6):1402-1407. PubMed ID: 29145068
[TBL] [Abstract][Full Text] [Related]
9. Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla.
Hofer SC; Ralvenius WT; Gachet MS; Fritschy JM; Zeilhofer HU; Gertsch J
Neuropharmacology; 2015 Nov; 98():78-89. PubMed ID: 25839900
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
11. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage.
Petrucci V; Chicca A; Glasmacher S; Paloczi J; Cao Z; Pacher P; Gertsch J
Sci Rep; 2017 Aug; 7(1):9560. PubMed ID: 28842619
[TBL] [Abstract][Full Text] [Related]
12. Tingenone, a pentacyclic triterpene, induces peripheral antinociception due to cannabinoid receptors activation in mice.
Veloso CC; Ferreira RCM; Rodrigues VG; Duarte LP; Klein A; Duarte ID; Romero TRL; Perez AC
Inflammopharmacology; 2018 Feb; 26(1):227-233. PubMed ID: 28889355
[TBL] [Abstract][Full Text] [Related]
13. Investigation of receptor binding and functional characteristics of hemopressin(1-7).
Dvorácskó S; Tömböly C; Berkecz R; Keresztes A
Neuropeptides; 2016 Aug; 58():15-22. PubMed ID: 26895730
[TBL] [Abstract][Full Text] [Related]
14. Binding of the hemopressin peptide to the cannabinoid CB1 receptor: structural insights.
Scrima M; Di Marino S; Grimaldi M; Mastrogiacomo A; Novellino E; Bifulco M; D'Ursi AM
Biochemistry; 2010 Dec; 49(49):10449-57. PubMed ID: 21062041
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.
Bátkai S; Pacher P; Járai Z; Wagner JA; Kunos G
Am J Physiol Heart Circ Physiol; 2004 Aug; 287(2):H595-600. PubMed ID: 15059774
[TBL] [Abstract][Full Text] [Related]
16. (m)RVD-hemopressin (α) and (m)VD-hemopressin (α) improve the memory-impairing effect of scopolamine in novel object and object location recognition tasks in mice.
Zhang R; Lao K; Lu B; Guo H; Cheng J; Chen P; Gou X
Peptides; 2021 Feb; 136():170442. PubMed ID: 33171279
[TBL] [Abstract][Full Text] [Related]
17. New Insights Into Peptide Cannabinoids: Structure, Biosynthesis and Signaling.
Riquelme-Sandoval A; de Sá-Ferreira CO; Miyakoshi LM; Hedin-Pereira C
Front Pharmacol; 2020; 11():596572. PubMed ID: 33362550
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the cannabinoid receptors by hemopressin peptides.
Bomar MG; Galande AK
Life Sci; 2013 Mar; 92(8-9):520-4. PubMed ID: 22884803
[TBL] [Abstract][Full Text] [Related]
19. Peltatoside Isolated from Annona crassiflora Induces Peripheral Antinociception by Activation of the Cannabinoid System.
Oliveira CD; Veloso CC; Ferreira RC; Lage GA; Pimenta LP; Duarte ID; Romero TR; Perez AC
Planta Med; 2017 Feb; 83(3-04):261-267. PubMed ID: 27574895
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
